Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sana Biotechnology, Inc.

https://sana.com/

Latest From Sana Biotechnology, Inc.

China's CARsgen Raises $400m In Third-Largest Biotech IPO This Year

Chinese CAR-T therapy developer raises new funds to progress pipeline in over-subscribed IPO which ranks as the third-largest globally in the biotech sector to date this year.

Financing China

Flagship's $3.37bn Fund To Grow First-In-Category Firms

Flagship, the investor behind COVID-19 success story Moderna, has raised a huge fund that will be used to create and develop its own companies before spinning them off.

Financing Business Strategies

Finance Watch: Cell And Gene Therapy Firms Raised Nearly $20bn In 2020

Private Company Edition: Venture capital mega-rounds continue a brisk pace with machine learning-based drug discovery firm insitro and gene therapy developer Graphite Bio among recent $100m-plus deals. Also, Argobio raised €50m to fund five start-ups in Europe. 

Financing Innovation

Finance Watch: SPAC Spree To Continue ‘For Foreseeable Future’

Public Company Edition: Merging with a special purpose acquisition corporation may be an attractive alternative to an initial public offering, but February’s vigorous IPO pace includes seven recent offerings that raised $480.8m in the US. Also, Cassava raised $200m and KalVista brought in $222.5m.

Financing Deals
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
UsernamePublicRestriction

Register